|
Hepatoblastoma
|
0.510 |
AlteredExpression
|
disease |
BEFREE |
To evaluate Bcl-xL, Bax, PCNA, cytokeratin 19 (CK-19), glycogen content and DNA ploidy expression in hepatoblastoma (HB) and their prognostic value.
|
20803149 |
2010 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We show that mono-allelic loss of pten in the probasin-driven-ErbB-2 model resulted in increased nuclear cyclin D1 and proliferating cell nuclear antigen levels and decreased disease latency compared to either individual genetic model and, unlike the probasin-driven-ErbB-2 mice, progression to adenocarcinoma.
|
19443706 |
2009 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Thirty-five adenomas and 60 adenocarcinomas were studied immunohistochemically concerning proliferating cell nuclear antigen positivity in tumor cell nuclei.
|
7956574 |
1994 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
These results demonstrated a progressive immunoreactivity for PCNA in the HP to AC sequence, while p53 positivity and aneuploidy seemed specific for colon carcinoma.
|
9673389 |
1998 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
A linear correlation between numbers of ISH signals and PCNA expression was not demonstrated, but there was a tendency of increasing PCNA positivity according to increasing numbers of ISH signals in adenocarcinomas of the lung and the tumor tissues which were over 50% positive PCNA expression.
|
7911024 |
1993 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Results suggest that the PCNA index in cervical and endometrial adenocarcinomas and the pretreatment tumor volume in endometrial adenocarcinoma appeared to be potentially useful in predicting the immediate response to the chemotherapy.
|
9159335 |
1997 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Mean PCNA expression was higher in squamous carcinomas than in adenocarcinomas but there was marked intra-tumour variation in PCNA index in almost all cases.
|
1351473 |
1992 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In order to explore the application value of DCE-MRI in clinical diagnosis and treatment, guide early clinical diagnosis, evaluate prognosis, guide clinical selection of treatment options and improve medical level, the expression of adenocarcinoma, its relationship with clinicopathology, and the significance of co-expression of the proliferating cell nuclear antigen (PCNA), Ki67 protein and cyclooxygenase 2 (COX-2) in breast cancer are analyzed.
|
31289003 |
2019 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Biopsies of all 10 metastatic tumours (3 melanoma, 4 carcinoma and 3 adenocarcinoma) as well as 4 glioblastoma multiforme were positive for PCNA immunoexpression and supported the replication of HSV1716.
|
12898637 |
2003 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Studies by PCNA (proliferating cell nuclear antigen) immunohistochemistry, showed that in over half of the gastric-type adenocarcinomas cases PCNA-positive cells tended to be localized within tumor tissues.
|
7903667 |
1993 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The staining differences between LMP tumors and adenocarcinomas with antibodies against Ki-67, PCNA, and P-glycoprotein were not statistically significant.
|
9398993 |
1997 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The authors examined three cell-biological parameters--DNA status, proliferating cell-nuclear antigen (PCNA) immunostaining, and argyrophilic nucleolar-organizer region (AgNOR) counts--in surgically resected, formalin-fixed, paraffin-embedded urachal adenocarcinomas from 41 patients.
|
8600037 |
1996 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
A surprising finding was that S-phase percentage in adenocarcinomas was not parallel with PCNA-positive tumor cell numbers.
|
7729290 |
1995 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The expression of proliferating cell nuclear antigen and p53 protein was analysed by immunocytochemical methods (PC10, CM1 antisera) in 139 patients with T1-2M0 prostatic adenocarcinomas followed-up for > 12 years. p53 protein was expressed in 21 (15%) tumours (15%), the fraction of positive nuclei being very low (mean SE, 1% +/- 0.7%).
|
7913085 |
1994 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The tumor's cellularity, the Ki-67 positivity rate and PCNA, together with the clinical stage and the histological differentiation bring extra pieces of useful information in order to anticipate the evolution and the prognosis of lung cancer.
|
29940632 |
2018 |
|
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression of proliferating cell nuclear antigen in lung cancer: a systematic study and correlation with DNA ploidy.
|
1351473 |
1992 |
|
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Cyclin E expression negatively affects lung cancer prognosis.
|
17360482 |
2007 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cyclin E-driven transgenic lung cancers expressed a gene profile implicating HH pathway activation.
|
22923130 |
2012 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data suggest that targeting PCNA with PCNA-I1S may provide a novel approach for enhancing the efficacy of chemotherapy and radiation therapy in treatment of human prostate and lung cancer.
|
31600334 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of TIM-4 promoted lung cancer cell growth and proliferation, and upregulated the expression of PCNA, cyclin A, cyclin B1 and cyclin D1, accompanied by accumulation of lung cancer cells in S phase.
|
26512878 |
2015 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cyclin E transgenic mice: discovery tools for lung cancer biology, therapy, and prevention.
|
21149327 |
2010 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, our results unraveled a novel regulatory of GSK3β by PCNA and provided a promising direction for treatment of lung cancer.
|
31607135 |
2020 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To examine the role of elevated glucose uptake in lung cancer, we performed PCR amplification of 2 facilitative glucose transporter genes (GLUT1 and GLUT3) and immunohistochemical staining for GLUT1, proliferating cell nuclear antigen (PCNA), and sialyl Lewis x (sLe(x)) on tumor specimens from 327 patients with lung cancer who underwent surgical resection from 1980 to 1993.
|
9133454 |
1997 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Prognostic role of cyclin D1 in lung cancer. Relationship to proliferating cell nuclear antigen.
|
10101007 |
1999 |
|
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The reverse transcription quantitative polymerase chain reaction analysis revealed that PCNA‑1 was significantly upregulated (up to 5‑fold) in the lung cancer cells (P<0.05), and the overexpression of miR‑204 caused the downregulation of PCNA‑1 in A549 lung cancer cells.
|
30628638 |
2019 |